StockData
Genmab A/S logo

Genmab A/S (GMAB) KPIs and segments

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

KPIs & segments

Operating metrics and segments that drive Genmab A/S's business · fiscal year ends December 31

Genmab A/S KPIs at a glance: 76 operating metrics, including EPKINLY / TEPKINLY Global Net Sales, Genmab Proprietary Net Product Sales and Total Royalty Revenue Earned by Genmab, drawn from 76 source documents, alongside revenue by segment, product and region from SEC filings. Each figure links to the document it came from. All metrics shows the full sheet; Core narrows it to segments and headline KPIs. The segment tables also offer a trailing-twelve-month view.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Segments, headline KPIs and every operating metric from filings, earnings releases and presentations.

Add to chartMetric
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
EPKINLY / TEPKINLY Global Net Sales (Genmab & AbbVie)($M)3
1791751371351221219078826952
EPKINLY U.S. & Japan Net Product Sales (Recognized by Genmab)($M)
139136106107971007574706247
TEPKINLY International Net Sales by AbbVie (Royalty Territory)($M)
4039312725211541275
EPKINLY Collaboration Profit-Sharing Balance Paid to AbbVie($M)
68665051464735
Genmab Proprietary Net Product Sales (EPKINLY & Tivdak)($M)2
1491451161181041017574706247
Tivdak Japan & Europe Net Product Sales (Recognized by Genmab)($M)
1091011710
Tivdak Global Net Sales (Genmab & Pfizer Combined)($M)
474539424533
Total Royalty Revenue Earned by Genmab($M)4
991966742883841789589715691659452
DARZALEX / DARZALEX FASPRO Royalty Revenue (from J&J)($M)
751744562699656638450577557538347
Kesimpta Royalty Revenue (from Novartis)($M)
1491431161231221089095848064
TEPEZZA Royalty Revenue (from Amgen)($M)
3631263030202528292326
Other Marketed Antibody Royalties (RYBREVANT, TECVAYLI, TALVEY & TEPKINLY)($M)
5548383133232415211815
DARZALEX Global Net Sales by J&J (Underlying Royalty Base)($M)
4,2394,2073,9643,9033,6723,5393,2373,0843,0162,8782,6922,550
Kesimpta Global Net Sales by Novartis (Underlying Royalty Base)($M)
1,4841,4241,1641,2281,2221,077899950838799637
TEPEZZA Global Net Sales by Amgen (Underlying Royalty Base)($M)
526576490457560505381460488479424
Employees at Period-End (FTEs)2
3,2443,1193,0883,0292,6812,6392,6382,6822,6352,5262,2862,204
R&D Employees at Period-End (FTEs)
2,0812,0562,0272,0891,8411,8301,8371,8861,8531,7741,6011,541
SG&A & Commercial Employees at Period-End (FTEs)
1,1631,0631,061940840809801796782752685663
Approved Antibody Medicines Powered by Genmab Science
8888
Total Revenue by Collaboration Partner & Product Channel($M)6
1,0381,010780940918824640849746717556
J&J / Janssen Collaboration & Royalty Revenue($M)
794783592734694656481601575554361
Novartis Collaboration & Royalty Revenue($M)
14914411712412210991179848164
Roche Collaboration & Royalty Revenue($M)
3631263030212528302326
Pfizer Collaboration Profit-Share & Milestone Revenue($M)
2023161719221921192017
BioNTech R&D Reimbursement Revenue($M)
24064111919343737
Direct Net Product Sales & Other Collaboration Counterparties($M)
272516713020000
Collaboration Profit-Sharing Revenue (Pfizer Tivdak U.S.)($M)2
1722141617211617151614
R&D Cost Reimbursement Revenue from Partners($M)
15128107132323394240
Development, Regulatory & Commercial Milestone Revenue($M)
510163153112941050
Full-Year Revenue Guidance — Midpoint (As Issued Each Quarter)($M)8
4,4254,4254,2304,2303,6003,6003,500
Full-Year Revenue Guidance — Low End($M)
4,3254,3254,0654,0653,5003,5003,340
Full-Year Revenue Guidance — High End($M)
4,5254,5254,3954,3953,7003,7003,660
Full-Year Royalty Revenue Guidance — Midpoint($M)
3,6873,6873,5633,5633,0173,0172,900
Full-Year Net Product Sales & Collaboration Revenue Guidance — Midpoint($M)
618618522522445445438
Full-Year Milestones & Reimbursement Guidance — Midpoint($M)
120120145145138138162
Full-Year Gross Profit Guidance — Midpoint($M)
4,1054,1053,9603,9603,3703,3703,270
Full-Year Operating Expenses Guidance — Midpoint($M)
-2,880-2,880-2,810-2,810-2,140-2,140-2,140
Full-Year Operating Profit Guidance — Midpoint($M)
1,2251,2251,1501,1501,2301,2301,130
Common Shares Outstanding at Period-End (Excl. Treasury Shares)
62,405,85562,353,25264,243,33364,238,40864,206,34964,154,25466,197,24466,187,18666,176,83166,136,90966,122,96466,074,535
RSU Program — Unvested Units Outstanding at Year-End2
RSUs Granted During Period
13,79415,894625,5146,93314,3533,320633,505
RSUs Vested / Settled During Period
6,27673,188150,76327,20418,09611,972168,850
Warrant Program — Warrants Outstanding at Year-End2
Warrants Granted During Period
13,33115,494493,7967,3779,6813,636526,694
Warrants Exercised During Period
52,6032,53112,31332,05952,09533,86310,058
Receivables Related to Collaboration Agreements($M)
992969755907
Trade Receivables Related to Direct Product Sales($M)
11912510696
Commercial Inventories (Raw Materials, WIP & Finished Goods)($M)
30182118
Accrued Clinical Trial & External R&D Liabilities($M)
300340355410
Payables Related to Collaboration Agreements($M)
90988179
Accrued Bonuses & Staff Cost Liabilities($M)
14110681171
Total Contract Liabilities (Deferred Collaboration Revenue)2
Non-Current Contract Liabilities($M)
82888895
Current Contract Liabilities($M)
19212424
Total Goodwill & Intangible Assets (Carrying Amount)($M)4
9,1979,2279,3039,478
Acquired In-Process R&D (Rina-S & Petosemtamab IPR&D)($M)
8,2378,2608,3228,474
Acquired Antibody & ADC Technology Platforms($M)
494498511529
Goodwill($M)
355355355355
Licenses, Commercial Rights & Patents($M)
111114115120
Total Merus Acquisition Borrowings (Carrying Amount)($M)4
4,9925,1355,2085,274
Term Loan B Credit Facility (Floating SOFR)($M)
1,6741,8071,8701,914
6.250% Senior Secured Notes due 2032($M)
1,4391,4361,4361,441
7.250% Senior Unsecured Notes due 2033($M)
953952952957
Term Loan A Credit Facility (Amortizing)($M)
926940950962
Merus N.V. Total Revenue (Pre-Acquisition)1
12,150.008,828.0026,488.009,140.0011,772.007,332.007,889.00
Merus Collaboration Revenue (Gilead, Incyte, Lilly, Partner Therapeutics)
11,867.008,828.0013,148.009,140.0011,772.007,332.007,889.00
Merus N.V. Total R&D Expense (Pre-Acquisition)1
80,017.0093,926.0080,116.0074,426.0063,239.0049,119.0038,584.00
Merus Direct External Program R&D Costs3
57,355.0072,961.0059,658.0051,696.0045,563.0037,309.0028,500.00
Petosemtamab (MCLA-158, EGFRxLGR5) External R&D Spend
49,919.0068,967.0048,827.00104,406.000.000.000.00
Zenocutuzumab / BIZENGRI (MCLA-128, HER2xHER3) External R&D Spend
2,765.00-1,916.007,571.0032,831.000.000.000.00
MCLA-129 (EGFRxc-MET) External R&D Spend
1,835.002,942.00848.0015,751.000.000.000.00
Merus General & Administrative Expense
28,611.0025,252.0022,112.0023,366.0020,765.0022,587.0016,114.00
Merus Operating Loss
-96,478.00-110,350.00-75,740.00-88,652.00-72,232.00-64,374.00-46,809.00
Merus Net Loss
-95,520.00-158,218.00-96,474.00-30,923.00-99,905.00-50,042.00-34,456.00
Merus Cash & Cash Equivalents
367,491.00442,791.00197,199.00293,294.00
Merus Current Marketable Securities
268,441.00267,433.00261,126.00243,733.00
Cumulative Interventional Clinical Studies Sponsored (Genmab & Merus)7
10810299959289858177696665
Phase 3 Sponsored Interventional Studies
211917171514131311887
Phase 2 Sponsored Interventional Studies
686665646361585554504848
Phase 1 Sponsored Interventional Studies
15131310101010109877
Epcoritamab Sponsored Clinical Studies
373434343332302726211918
Tisotumab Vedotin Sponsored Clinical Studies
101010101010999999
Rinatabart Sesutecan (Rina-S) Sponsored Clinical Studies
885532221111
Petosemtamab Sponsored Clinical Studies
866555555333
Cumulative Planned/Actual Patient Enrollment Across Sponsored Trials6
20,25818,50217,57217,27016,41415,25015,12314,35513,53111,64511,57310,478
Phase 3 Sponsored Trial Patient Enrollment
10,1078,5477,7777,7777,1616,5016,4016,4015,6263,9273,9272,832
Epcoritamab Sponsored Trial Patient Enrollment
7,1877,1037,1037,1037,0317,0096,9836,2186,1925,6495,5984,503
Tisotumab Vedotin Sponsored Trial Patient Enrollment
1,6221,6221,6221,6221,6221,6221,5221,5221,5221,5221,5221,522
Rina-S Sponsored Trial Patient Enrollment
3,9103,9102,9802,9802,1961,5361,5361,536952952952952
Petosemtamab Sponsored Trial Patient Enrollment
3,5451,9851,9851,9851,9851,9851,9851,9851,985665665665
Acasunlimab Sponsored Trial Patient Enrollment
764764764764764764763763572572572572
J&J Reported DARZALEX Worldwide Net Sales (U.S. vs. International Split)($M)4
4,2394,2073,9643,9033,6723,5393,2373,0843,0162,8782,6922,550
J&J Reported DARZALEX U.S. Net Sales($M)
2,5282,4352,2082,3322,0882,0171,8291,7991,6841,6411,4641,395
J&J Reported DARZALEX International Net Sales($M)
1,7111,7721,7561,5711,5841,5211,4091,2851,3321,2371,2281,155
J&J Reported DARZALEX Operational YoY Growth (Constant Currency)(%)
15.6%17.6%17.8%24.1%19.9%21.5%22.5%23.5%22.9%21.3%21.0%22.2%
J&J Reported DARZALEX Reported YoY Growth(%)
15.4%18.9%22.5%26.6%21.7%23.0%20.3%20.9%20.7%18.4%18.9%22.4%
J&J Reported RYBREVANT (Amivantamab, DuoBody) Worldwide Net Sales($M)4
320289257216198179141122896947
J&J Reported RYBREVANT U.S. Net Sales($M)
201190175146136139113101685236
J&J Reported RYBREVANT International Net Sales($M)
11999827061412821211711
J&J Reported TECVAYLI (Teclistamab, DuoBody) Worldwide Net Sales($M)2
312260202176177166151146135135133126
J&J Reported TECVAYLI U.S. Net Sales($M)
236186127110115114105108105104101102
J&J Reported TECVAYLI International Net Sales($M)
777474666252463830303324
J&J Reported TALVEY (Talquetamab, DuoBody) Worldwide Net Sales($M)2
1711741521491221068685756958
J&J Reported TALVEY U.S. Net Sales($M)
11211210110585826868645950
J&J Reported TALVEY International Net Sales($M)
59625144372418171298
Novartis Reported Kesimpta Worldwide Net Sales & Prescription Share Gains($M)4
1,4841,4241,1641,2281,2221,077899950838799637641
Novartis Reported Kesimpta Constant-Currency YoY Growth(%)
22.0%32.0%26.0%27.0%44.0%33.0%43.0%49.0%28.0%65.0%66.0%73.0%
Novartis Reported Kesimpta USD YoY Growth(%)
21.0%32.0%29.0%29.0%46.0%35.0%41.0%48.0%28.0%63.0%66.0%74.0%
Kesimpta U.S. Overall MS Total Prescription (TRx) Share Gain YoY (pts)(%)
3.0%2.0%2.0%2.2%2.3%
Kesimpta U.S. B-Cell Segment TRx Share Gain YoY (pts)(%)
4.5%2.5%1.5%2.4%
Spot Exchange Rate: DKK per USD (Period-End, FRED DEXDNUS)
6.596.556.496.366.366.346.917.206.696.966.916.74
Spot Exchange Rate: USD per EUR (Period-End, FRED DEXUSEU)($)
1.131.141.151.171.171.181.081.041.111.071.081.11
Spot Exchange Rate: JPY per USD (Period-End, FRED DEXJPUS)
157.25162.61159.08156.80147.97144.17149.90157.37143.25160.88151.22140.92
U.S. Producer Price Index: Pharmaceutical Preparation Mfg (BLS PCU325412325412)
929.30926.20926.00919.30918.70914.80916.50918.50918.10914.00909.00896.40
U.S. Producer Price Index: Biological Product Mfg (BLS PCU325414325414)
267.20266.30266.30264.10264.10261.90261.90258.30258.00255.20256.80254.50
Consolidated Revenue (USD Presentation Basis)($M)10
1,1871,1558961,0581,022925715923816779603
Cost of Product Sales (USD)($M)
-88-84-65-81-58-57-42-48-40-28-27
Research & Development Expenses (USD)($M)
-451-459-440-521-354-364-359-382-336-361-335
Selling, General & Administrative Expenses (USD)($M)
-196-205-166-208-148-144-126-179-127-129-125
Acquisition & Integration-Related Charges (USD)($M)
-10-32-45-185000-4-3-250
Total Costs & Operating Expenses (USD)($M)
-756-780-716-1,000-563-565-527-613-506-543-487
Consolidated Operating Profit (USD)($M)
43137518058459360188310310236116
Net Financial Items (USD)($M)
-77-80-106-3236356207-5771133
Consolidated Net Profit (USD)($M)
3423035331401336195552186203192
Basic Net Profit per Share (USD)($)
5.584.940.846.515.443.062.943.152.96
Diluted Net Profit per Share (USD)($)
5.514.910.836.465.423.052.923.132.94
Consolidated Total Assets (USD Presentation Basis)($M)5
12,93612,51512,37612,8737,0216,4646,5866,4145,9555,5445,319
Cash & Cash Equivalents (USD)($M)
1,8601,5031,5211,7151,7611,2961,6191,3809526222,127
Marketable Securities (USD)($M)
00001,6501,6031,6071,5741,6481,6372,163
Shareholders' Equity (USD)($M)
6,3335,9575,6825,8475,7515,3025,2965,1374,7934,4454,713
Net Cash Provided by Operating Activities (USD)($M)
52051330153662287389299219219
Investment in Tangible Assets / CapEx Cash Outflow (USD)($M)
-4-2-5-13-2-10-12-14-5-4-4

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
  • Genmab A/S reports on a calendar fiscal year ending December 31 (Q1: Mar 31, Q2: Jun 30, Q3: Sep 30, Q4: Dec 31). Effective January 1, 2025, Genmab changed its presentation currency from Danish Kroner (DKK) to U.S. Dollars (USD) and restated comparative figures.
  • Beginning Q3 2026, Genmab separated 'Amortization of acquired intangible assets' (-$14M in FY2025; -$35M in 9M 2026) from R&D expenses on the Consolidated Income Statement; Q4 2025 R&D is derived from full-year and 9M 2025 comparative columns reported on the identical reclassified basis in the Q3 2026 Interim Report.
  • On May 21, 2024, Genmab completed the $1.8B acquisition of ProfoundBio (adding Rina-S and Suzhou/Seattle R&D staff). On December 12, 2025, Genmab completed the $8.0B acquisition of Merus N.V. (adding Phase 3 petosemtamab, FDA-approved BIZENGRI, 288 FTEs, and $5.5B of acquisition debt).
  • Consolidated year-end and quarterly FTEs include Merus N.V. from Q4 2025 (3,029 FTEs at year-end 2025; 3,244 at Q3 2026), whereas audited ESRS S1 sustainability workforce tables in the FY2025 Statutory Annual Report exclude 288 Merus FTEs pending HR system integration.

Not shown because recent periods are missing (19)

  • EPKINLY U.S. Payer Coverage (>97% of commercial and Medicare lives covered on Q3 2026 earnings call) — excluded as a bound/inequality figure rather than an exact point metric
  • EPKINLY / TEPKINLY Cumulative Global Regulatory Approvals (>65 approvals across >40 countries on Q2–Q3 2026 earnings calls) — excluded as bound/inequality disclosures
  • Clinical Pipeline Count ('over a dozen clinical-stage candidates' / 'more than 20 trials') — excluded as bound wording; exact registered study counts are tracked via NIH ClinicalTrials.gov in Group 9
  • Recurring Revenue Share of Total Revenue (96% cited on Q3 2025 earnings call) — disclosed in only a single quarterly call, lacking 3 consecutive periods
  • License Revenue ($10M one-off upfront recognition in Q3 2026; $0 in prior periods) — active in only 1 quarter, lacking 3 consecutive periods
  • Amortization of Acquired Intangible Assets (separated starting Q3 2026: -$11M in Q3 2026, -$35M in 9M 2026, -$14M in FY2025) — individual Q1 2026 and Q2 2026 quarters were not separately restated
  • Quarterly Partner-by-Partner Disaggregation for AMGN, ABBV, and PFE U.S./International Drug Splits — annual Form 10-K regional splits through FY2025 are included in Group 9 while quarterly global totals through Q3 2026 are shown in Groups 1–2
  • Pre-2025 DKK Financial Guidance Snapshots — excluded from the USD guidance table due to the January 1, 2025 presentation currency switch from DKK to USD
  • Single-Readout Clinical Trial Efficacy Endpoints (e.g., LiGeR-HN1 & EPCORE FL-1 hazard ratios and ORR percentages) — one-time trial event readouts rather than recurring period-by-period operational series
  • Parent vs. Consolidated Subtraction for Total Assets, Shareholders' Equity, and Operating Cash Flow — omitted because parent equity investments in subsidiaries ($10,418M in FY2025) and intercompany balances distort subtraction
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2016 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2017 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2018 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2019 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2020 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2021 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2022 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2023 (cash-and-equivalents)
  • Omitted derived XBRL baseline record: Legacy DKK cash-and-short-term-investments: FY2024 (cash-and-equivalents)

Data updated 2026-11-11.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Latest source documents

The documents cited most often for Genmab A/S's most recent figures

See a number that looks wrong?